Evonetix Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
54
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$28.2M
- Investors
-
15
Evonetix General Information
Description
Operator of a biotechnology company intended to synthesize DNA at higher accuracy and scale. The company's platform places DNA synthesis in the hands of every researcher and changes how DNA is accessed, made, and used for gene synthesis, enabling scientists to use synthetic biology on a scale not currently possible.
Contact Information
Website
www.evonetix.comCorporate Office
- 9a Coldham's Business Park
- Norman Way
- Cambridge CB1 3LH
- England, United Kingdom
Corporate Office
- 9a Coldham's Business Park
- Norman Way
- Cambridge CB1 3LH
- England, United Kingdom
Evonetix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 07-Feb-2023 | $28.2M | Completed | Generating Revenue | ||
| 6. Grant | 01-Jun-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 17-Apr-2020 | Completed | Generating Revenue | |||
| 4. Grant | 02-Jul-2018 | Completed | Startup | |||
| 3. Early Stage VC (Series A) | 30-Jan-2018 | Completed | Startup | |||
| 2. Early Stage VC | 20-Jul-2016 | Completed | Startup | |||
| 1. Angel (individual) | 01-Jan-2015 | Completed | Startup |
Evonetix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference | ||||||||
| B2 Preferred | ||||||||
| B1 Preferred | ||||||||
| B Preferred | ||||||||
| A Preferred | ||||||||
| A Preferred | 859,433 | $0.012266 | $12.14 | $12.14 | 1x | $12.14 | 17.45% | |
| Pref A Ordinary | 500,000 | $0.012266 | $4.91 | $4.91 | 1x | $4.91 | 10.15% |
Evonetix Comparisons
Industry
Financing
Details
Evonetix Competitors (21)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DNA Script | Venture Capital-Backed | Le Kremlin-Bicêtre, France | ||||
| New England Biolabs | Corporation | Ipswich, MA | ||||
| Oxford Nanopore Technologies | Formerly VC-backed | Oxford, United Kingdom | ||||
| Twist Bioscience | Formerly VC-backed | South San Francisco, CA | ||||
| ToolGen | Corporation | Seoul, South Korea |
Evonetix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Evonetix Patents
Evonetix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202400456-D0 | Reaction control apparatus and method | Pending | 12-Jan-2024 | ||
| GB-202319165-D0 | Cleavable protecting and linker groups | Pending | 14-Dec-2023 | ||
| GB-202313749-D0 | Enzymes and methods | Pending | 08-Sep-2023 | ||
| GB-202300626-D0 | Hybridisation detection | Inactive | 16-Jan-2023 | ||
| GB-202211750-D0 | Reaction duration control for reaction performed on biomolecule samples | Pending | 11-Aug-2022 | B01J19/0046 |
Evonetix Executive Team (7)
| Name | Title | Board Seat |
|---|---|---|
| Andrew Diston | Chief Executive Officer & Board Member | |
| Matthew Hayes Ph.D | Co-Founder, Chief Technology Officer and Board Member | |
| Malcolm Gates | Vice President of Finance |
Evonetix Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Andrew Diston | Evonetix | Chief Executive Officer & Board Member | |
| Hermann Hauser Ph.D | Self | Board Observer | |
| James Tananbaum MD | Foresite Capital | Board Member | |
| Jason Pontin | DCVC | Board Member | |
| Mammen Eapen | Cambridge Consultants | Board Member |
Evonetix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Evonetix Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Foresite Capital | Growth/Expansion | Minority | ||
| Esprit Nominees | Other | Minority | ||
| Foresight Capital | Venture Capital | Minority | ||
| MNL Nominees | Corporation | Minority | ||
| Morningside Venture Investments Limited | Corporation | Minority |
Evonetix FAQs
-
When was Evonetix founded?
Evonetix was founded in 2015.
-
Who is the founder of Evonetix?
Matthew Hayes Ph.D and Joseph Brennan Ph.D are the founders of Evonetix.
-
Who is the CEO of Evonetix?
Andrew Diston is the CEO of Evonetix.
-
Where is Evonetix headquartered?
Evonetix is headquartered in Cambridge, United Kingdom.
-
What is the size of Evonetix?
Evonetix has 54 total employees.
-
What industry is Evonetix in?
Evonetix’s primary industry is Biotechnology.
-
Is Evonetix a private or public company?
Evonetix is a Private company.
-
What is the current valuation of Evonetix?
The current valuation of Evonetix is .
-
What is Evonetix’s current revenue?
The current revenue for Evonetix is .
-
How much funding has Evonetix raised over time?
Evonetix has raised $67.8M.
-
Who are Evonetix’s investors?
Foresite Capital, Esprit Nominees, Foresight Capital, MNL Nominees, and Morningside Venture Investments Limited are 5 of 15 investors who have invested in Evonetix.
-
Who are Evonetix’s competitors?
DNA Script, New England Biolabs, Oxford Nanopore Technologies, Twist Bioscience, and ToolGen are some of the 21 competitors of Evonetix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
